Sensient Technologies's 15min chart shows Bollinger Bands Narrowing and Bearish Marubozu signal.

Based on the 15-minute chart of Sensient Technologies, a narrowing of the Bollinger Bands and a bearish Marubozu formation has been observed at 10:45 AM on October 21, 2025. This suggests a decrease in the magnitude of stock price fluctuations, indicating that sellers are currently in control of the market. Furthermore, this bearish momentum is likely to persist.

Talphera Inc. (TLPH), a specialty pharmaceutical innovator focused on developing therapies for critical care environments, has recently announced significant updates. These developments include a private placement financing round and notable milestones in their clinical trials.

Private Placement Financing

On September 8, 2025, Talphera announced a private placement financing of up to $29 million, led by CorMedix Inc. The financing includes $17 million in the first closing, with a potential $12 million in a second tranche upon achieving the primary endpoint in the NEPHRO CRRT study . The first closing involves issuing 25,036,363 shares at $0.55 per share and 5,845,455 pre-funded warrants at $0.549. CorMedix receives a 60-day exclusivity period to negotiate Talphera's acquisition following NEPHRO study results and gains board nomination rights.

Clinical Trial Milestones

Talphera has also made progress in its pivotal NEPHRO CRRT clinical trial. On August 8, 2025, the company announced that it had reached a significant milestone by enrolling 17 patients, representing approximately 25% of the targeted 70-patient enrollment . This achievement fulfills a requirement for the second tranche of their March 2025 three-tranche financing agreement. The company reports an accelerated recruitment rate from new profile clinical sites, with over 90% of enrolled patients coming from these new locations.

Financial Results

In its second quarter 2025 financial results, Talphera reported a net loss of $3.5 million ($0.10 per share), improved from $3.8 million in the same period last year. Operating expenses decreased to $3.7 million from $4.3 million year-over-year. The company secured a three-tranche financing of up to $14.8 million, with the first tranche of $4.9 million closed in April 2025 .

Looking Ahead

Talphera expects to complete the NEPHRO CRRT study by the end of 2025, with six additional sites expected to begin enrollment in Q3. The company anticipates submitting a PMA early next year with potential approval in the second half of 2026.